Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of Deferoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | GAA | P10253 | 1/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.97 |
| ▸ | KDM4A | O75164 | 10/20 | 0.90 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.90 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.90 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.90 |
| ▸ | PAOX | Q6QHF9 | 2/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.37 |
| ▸ | CASP2 | P42575 | 1/20 | 0.35 |
| ▸ | KDM5A | P29375 | 1/20 | 0.34 |
| ▸ | KDM7A | Q6ZMT4 | 1/20 | 0.34 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.34 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30036991 | 0.99 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL1699778 | 0.99 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL119982 | 0.99 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL7715593 | 0.99 | KDM4E (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL3953046 | 0.97 | KDM4E (0.97) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL2165915 | 0.96 | KDM4E (0.95) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL1034134 | 0.96 | KDM4E (0.95) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL9555338 | 0.95 | KDM4E (0.93) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| Deferoxamine SCHEMBL34571 | 0.95 | KDM4A (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A | |
| SCHEMBL21051754 | 0.95 | KDM4A (1.00) | KDM4ELMNAGAASMN1; SMN2KDM4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0614376-A1 | A METHOD AND FORMULATIONS USEFUL TO IMPROVE THE STUDY OF HUMAN BODY CAVITIES | DIBRA S.p.A. (IT) | 1994-09-14 | — | — | EP | disclosed |
| WO-1993010821-A1 | A METHOD AND FORMULATIONS USEFUL TO IMPROVE THE STUDY OF HUMAN BODY CAVITIES | BRACCO S.P.A. (IT) | 1993-06-10 | — | — | WO | disclosed |
| US-4758422-A | Ferrioxamine paramagnetic contrast agents for MR imaging | SALUTAR INC. (US) | 1988-07-19 | — | — | US | disclosed |
| EP-0235361-A2 | Ferrioxamine paramagnetic contrast agents for MR imaging | SALUTAR, INC. (US) | 1987-09-09 | — | — | EP | disclosed |